Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,950 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,826 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04185831 | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial(MEGALiT) | unknown | Phase 2 | 167 | Uppsala University HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566391 | Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma | unknown | Phase 2 | 35 | European Institute of OncologyOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT06149169 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | unknown | Phase 2 | 10 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03612232 | Cabozantinib in Advanced Adrenocortical Carcinoma(CaboACC) | unknown | Phase 2 | 37 | Wuerzburg University HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06561022 | Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping(abemaSNF1/3) | unknown | Phase 2 | 260 | Fudan UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05182866 | ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer | unknown | Phase 2 | 9 | Rakuten Medical, Inc.INDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT03658785 | Immunotherapy for the Treatment of Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Tongji HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04524208 | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3(CABONEN) | unknown | Phase 2 | 45 | Karsten GavenisOTHER | 2 | Aug 13, 2024 | clinicaltrials |
| NCT05833815 | Addition of Everolimus to Standard of Care in Carcinoma Gallbladder | unknown | Phase 2 / Phase 3 | 56 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06463522 | Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)(COALITION) | unknown | Phase 1 / Phase 2 | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06341309 | Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT06353360 | TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. | unknown | Phase 2 | 30 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06475326 | Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 87 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06479473 | Radiotherapy to All Residual Lesions After Chemoimmunotherapy | unknown | Phase 1 / Phase 2 | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06543836 | ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer | unknown | Phase 2 | 68 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06546280 | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | unknown | Phase 2 | 38 | Zhujiang HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04282031 | A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | unknown | Phase 1 / Phase 2 | 224 | Beta Pharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04787289 | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | unknown | Phase 2 | 244 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04951583 | Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma(FMT-LUMINATE) | unknown | Phase 2 | 45 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06540937 | Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04636008 | Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06498752 | MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer | unknown | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06539559 | Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer | unknown | Phase 2 | 60 | Wang JiayuOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06505278 | The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy | unknown | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT04483284 | Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06468267 | RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT05412589 | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC | unknown | Phase 2 | 35 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06530784 | Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma | unknown | Phase 2 | 36 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04679480 | Anti-PD1-antibody and Pulsed HHI for Advanced BCC | unknown | Phase 2 | 20 | Reinhard DummerOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06427330 | Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia | unknown | Phase 2 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06527495 | Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 150 | Assiut UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT05842785 | TSN222 in Subjects With Advanced Solid Tumors or Lymphomas | unknown | Phase 1 / Phase 2 | 162 | Tyligand Bioscience (Shanghai) LimitedINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT05554276 | Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer(PD-1) | unknown | Phase 2 | 36 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06519110 | Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations(CVL009-C2001) | unknown | Phase 2 | 60 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | Jul 25, 2024 | clinicaltrials |
| NCT06516445 | SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC | unknown | Phase 2 | 33 | Huazhong University of Science and TechnologyOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04739618 | Metastatic Solid Cancer Clinical Trial | unknown | Phase 2 | 32 | ImmunSYS, LLCOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT06331455 | Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection(SUPER) | unknown | Phase 2 | 12 | Marc de PerrotOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 138 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT04303988 | A Phase II Study of Triple-negative Breast Cancer Brain Metastases. | unknown | Phase 2 | 35 | Fudan UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04318730 | Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma | unknown | Phase 2 | 21 | West China HospitalOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05271292 | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.(SCLC) | unknown | Phase 1 / Phase 2 | 36 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503094 | CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors | unknown | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05389527 | Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma(NeoLeap-HCC) | unknown | Phase 2 | 43 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT05675787 | Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia | unknown | Phase 2 | 82 | Peking University People's HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 22, 2024source: clinicaltrials